Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · January 01, 2024

Treatment With AG019 Alone or in Combination With Teplizumab in Patients With Recent-Onset Type 1 Diabetes



Additional Info

A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab
Diabetologia 2024 Jan 01;67(1)27-41, C Mathieu, A Wiedeman, K Cerosaletti, SA Long, E Serti, L Cooney, J Vermeiren, S Caluwaerts, K Van Huynegem, L Steidler, S Blomme, P Rottiers, GT Nepom, KC Herold

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading